CDXC
ChromaDex Corporation · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Other
- Website chromadex.com
- Employees(FY) 113
- ISIN US1710774076
Performance
-11.24%
1W
+3.23%
1M
+99.11%
3M
+109.69%
6M
+369.23%
YTD
+397.04%
1Y
Profile
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Technical Analysis of CDXC 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-03 08:34
- 2024-12-02 19:34
- 2024-11-22 09:15
- 2024-11-19 09:03
- 2024-11-15 06:06
3 US Growth Companies With Strong Insider Confidence(Simply Wall St.)
- 2024-11-14 08:32
- 2024-11-13 19:32
- 2024-11-08 07:09
- 2024-11-07 23:00
- 2024-11-07 08:32
- 2024-11-07 06:28
- 2024-11-06 19:32
- 2024-11-04 20:15
- 2024-11-02 09:26
ChromaDex Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-10-31 23:02
- 2024-10-31 16:04
- 2024-10-31 05:15
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates(Yahoo Finance)
- 2024-10-31 04:09
ChromaDex: Q3 Earnings Snapshot(Yahoo Finance)
- 2024-10-31 04:04
- 2024-10-29 21:20
- 2024-10-27 20:32
- 2024-10-23 20:32
- 2024-10-23 13:31
ChromaDex Leads The Charge With 2 Other US Penny Stocks To Watch(Simply Wall St.)
- 2024-10-22 20:34
- 2024-10-17 21:40
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?(Yahoo Finance)
- 2024-10-14 20:32
- 2024-10-09 05:18
- 2024-09-26 04:12
- 2024-09-25 21:40
- 2024-09-19 20:32
ChromaDex Appoints Ozan Pamir as Chief Financial Officer(Businesswire)
Page 1 of 6
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.